申请人:Pfizer Inc.
公开号:US03966951A1
公开(公告)日:1976-06-29
Disclosed herein are novel esters of quinoxaline-1,4-dioxide of the structure ##SPC1## In which X is selected from the group consisting of a single bond, lower n-alkylene and --(CH.sub.2).sub.p --CH=CH--(CH.sub.2).sub.q -- where p and q may have integral values from zero to four with the proviso that p+q is less than or equal to four; A is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, lower alkoxy, fluorine, chlorine, bromine, iodine, cyano and trifluoromethyl; And R is selected from the group consisting of hydrogen, lower alkanoyl and .alpha.-hydroxy lower alkyl. When administered to animals, these compounds function as antibacterial agents, promote growth and improve feed efficiency. They are particularly useful in the prophylaxis and treatment of pasturellosis and salmonellosis and are notable for their extremely low toxicity in the test animal.
本发明涉及一种新的喹喔啉-1,4-二氧化物酯类,其结构为## SPC1 ##其中X选自由单键,较低n-烷基和-(CH.sub.2).sub.p-CH=CH-(CH.sub.2).sub.q-的群体,其中p和q可以具有从零到四的整数值,但是p+q小于或等于四; A选自氢、羟基、较低烷基、较低烷氧基、氟、氯、溴、碘、氰和三氟甲基的群体; R选自氢、较低脂肪酰基和α-羟基较低烷基的群体。当这些化合物被用于动物时,它们具有抗菌作用,促进生长并提高饲料效率。它们特别适用于预防和治疗病菌性鼻炎和沙门氏菌病,并以其在测试动物中极低的毒性而著称。